About: biomedicines

IMI chief: ‘We need to learn how to share data in a safe and ethical manner’

Ethicists, humanists, lawyers and patients should come together to understand the risk of data in healthcare and whether patients are willing to take that risk, Pierre Meulien told EURACTIV.com.

Regulators pave way for new wave of biosimilar drugs in Europe

European regulators have cleared the way for the first serious threat to the makers of multibillion-euro biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.

Medicines in emerging markets

Fast-growing economies such as China and India could provide lucrative new markets for Europe's pharmaceutical industry, but emerging nations are investing heavily in their own medicines sector and look set to challenge Western dominance of the healthcare market.

‘Me’ medicine

Developments in biomedicine should be greeted with caution, writes Donna Dickenson, professor emeritus of medical ethics and humanities at the University of London, 2006 winner of the International Spinoza Lens Award for contributions to public debate on ethics and author of 'Body Shopping: The Economy Fuelled by Flesh and Blood'.

Biopharma’s capacity crunch

Biopharma’s capacity crunch Over the next few years, the industry will be hard pressed to meet demand for promising new protein-based therapeutics that are now emerging from the laboratories. Manufacturing shortfalls in physical capacity and talent could spell lost revenues...

Dealmaking for Growth: How Biotech Firms Can Avoid the Tragedy of “Boom and Bust”

Dealmaking for Growth: How Biotech Firms Can Avoid the Tragedy of “Boom and Bust” “Biotech firms, once the darlings of the investment community, today find themselves between a rock and a hard place when it comes to accessing the resources...

A cure for clinical trials

A cure for clinical trials “Pharma companies often miss their deadlines when testing new drugs. The use of marketing techniques to manage the recruitment of patients for clinical trials could speed things up considerably.” The McKinsey Quarterly, 2002 Number 2...

Splicing a cost squeeze into the genomics revolution

Splicing a cost squeeze into the genomics revolution “Observers and analysts are looking forward to a profusion of innovative drugs, but they have paid far less attention to the business challenge of the new biology.” “ The McKinsey Quarterly, 2001...